» Articles » PMID: 18267072

Adenovirus Serotype 5 Hexon Mediates Liver Gene Transfer

Abstract

Adenoviruses are used extensively as gene transfer agents, both experimentally and clinically. However, targeting of liver cells by adenoviruses compromises their potential efficacy. In cell culture, the adenovirus serotype 5 fiber protein engages the coxsackievirus and adenovirus receptor (CAR) to bind cells. Paradoxically, following intravascular delivery, CAR is not used for liver transduction, implicating alternate pathways. Recently, we demonstrated that coagulation factor (F)X directly binds adenovirus leading to liver infection. Here, we show that FX binds to the Ad5 hexon, not fiber, via an interaction between the FX Gla domain and hypervariable regions of the hexon surface. Binding occurs in multiple human adenovirus serotypes. Liver infection by the FX-Ad5 complex is mediated through a heparin-binding exosite in the FX serine protease domain. This study reveals an unanticipated function for hexon in mediating liver gene transfer in vivo.

Citing Articles

Chimeric Ad5/35 oncolytic adenovirus overcome preexisting neutralizing antibodies and enhance tumor targeting efficiency.

Dai Z, Si Y, Xiong S, Li Y, Ye J, Gao Q Cancer Gene Ther. 2025; .

PMID: 40057574 DOI: 10.1038/s41417-025-00884-x.


In vivo targeted gene delivery using Adenovirus-antibody molecular glue conjugates.

Rice-Boucher P, Kashentseva E, Dmitriev I, Guo H, Tremblay J, Shoemaker C bioRxiv. 2025; .

PMID: 39974927 PMC: 11838440. DOI: 10.1101/2025.01.31.635969.


Extended receptor repertoire of an adenovirus associated with human obesity.

Liaci A, Chandra N, Vodnala S, Strebl M, Kumar P, Pfenning V PLoS Pathog. 2025; 21(1):e1012892.

PMID: 39883726 PMC: 11813153. DOI: 10.1371/journal.ppat.1012892.


CD46 Is a Protein Receptor for Human Adenovirus Type 64.

Wu E, Robertson A, Zhu H, Stasiak C, Murray-Nerger L, Romanoff E Viruses. 2025; 16(12.

PMID: 39772136 PMC: 11680334. DOI: 10.3390/v16121827.


An oncolytic HAdV-5 with reduced surface charge combines diminished toxicity and improved tumor targeting.

Wienen F, Nilson R, Allmendinger E, Peters S, Barth T, Kochanek S Mol Ther Oncol. 2025; 32(4):200909.

PMID: 39758252 PMC: 11699628. DOI: 10.1016/j.omton.2024.200909.